Glioblastoma

• Merck Sharp & Dohme LLC

  Company1 trialPhase 499 people

• AbbVie

  Company2 trialsPhase 3891 people

• Hoffmann-La Roche

  Company1 trialPhase 3921 people

• Johnpro Biotech, Inc.

  Company1 trialPhase 2/3288 people

• BPGbio

  Company1 trialPhase 250 people

• BreakBio Corp

  Company1 trialPhase 1/210 people

• Northwell Health

  1 trialPhase 3432 people

• NRG Oncology

  1 trialPhase 3265 people

National Institute of Neurological Disorders and StrokeUS$934.3k3 grants since 2023

• Investigating the role of sulfide oxidation and declining hydrogen sulfide in glioblastoma

  National Institute of Neurological Disorders and StrokeCleveland Clinic Lerner Com-cwruUS$34.1k2025–2028

• Extratumoral biological determinants that decrease survival in older adults with glioblastoma

  National Institute of Neurological Disorders and StrokeLoyola University ChicagoUS$385k2023–2028

• Hydrogen sulfide functions as a tumor suppressor in glioblastoma

  National Institute of Neurological Disorders and StrokeCleveland Clinic Lerner Com-cwruUS$515.1k2023–2028